Neratinib Promising for EarlyStage HER2 Breast Cancer But Has Caveats

Neratinib Promising for Early-Stage HER2+ Breast Cancer, But Has Caveats

Mohammed Rahman, MD, discusses ongoing efforts to optimize the use of neratinib in patients with HER2-positive breast cancer.

Original Article: Neratinib Promising for Early-Stage HER2+ Breast Cancer, But Has Caveats

More From BioPortfolio on "Neratinib Promising for Early-Stage HER2+ Breast Cancer, But Has Caveats"